"As we look to the second half of the year, we continue to make great progress in our retail expansion strategy, and we expect that our new manufacturing facility will come online during the fiscal third quarter," Mr. Song said. "We now have 22 Shining outlets that have been open at least one year, and all of these have demonstrated very strong growth year-over-year. As we accelerate our rollout of Shining outlets, we expect a significant increase in selling expenses. However, sales from existing outlets should help to offset increased expenses, as 60% of our retail sales typically occur during the second half of our fiscal year. The bulk additive business should continue to expand, as our new facility becomes operational and we are able to take on additional orders."
In October 2008, the Company announced it was approved to list shares of its common stock on the Nasdaq Global market. Shares began trading on Nasdaq on October 23 under the symbol "CHBT."
Also in October 2008, the Company announced that it has engaged the Shanghai office of KPMG Advisory (China) Limited to assist the Company in complying with the financial reporting and controls requirements of Sarbanes- Oxley Act Section 404 ("SOX 404"). KPMG Shanghai's engagement is designed to assist China-Biotics as it complies with SOX 404, which requires the Company and its external auditor to report on the adequacy of the Company's internal financial reporting and controls systems after documenting and testing financial reporting and control procedures.
The company will host a conference call at 9:00 a.m. EST on, Tuesday,
November 11, 2008, to discuss its financial results for the fiscal second
quarter ended September 30, 2008. To participate in the event by telephone,
please dial 888-241-0558 five to 10 mi
|SOURCE China-Biotics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved